ESCO1 and cervical carcinoma: However, the emergence of chemoresistance, peripheral neuropathy, nephrotoxicity, and hepatorenal toxicity to paclitaxel has posed significant challenges in cervical cancer treatment.[42] Here we showed that silence of either lncTUBA3FP or ESCO1 enhanced the sensitivity of cervical cancer cells to paclitaxel, as evidenced by reduced tumorigenesis and increased ferroptosis levels.